Azienda britannica di diagnostica molecolare gastrointestinale per la diagnosi precoce del cancro esofageo (dispositivo EndoSign).
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series B Cyted Health raised over €37 million in a Series B led by EQT Life Sciences and Advent Life Sciences for the US commercial expansion of its early esophageal cancer diagnostics. | $42.9M |